Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer
2 Jun 2018
Zoptarelin no better than doxarubicin for second-line advanced endometrial cancer
Editor’s Choice for May 2018
AKT inhibitors in research and application
Editor’s Choice for March 2018
Editor's Choice for February 2018
Immunotherapy and targeted treatments in breast cancer reviewed
Challenges in cervical radiotherapy
ESO-ESMO-ABC guidelines in metastatic breast cancer
BGICC conference highlights: Changing standards in breast and gynaecological cancers
Updates in trophoblastic neoplasia management
Guidelines and genomic factors for endometrial cancer
Recommendation guidelines in breast cancer resolution for the Eastern Mediterranean